LivingPhoenix Regenerative Technologies Development (Chengdu) Co., Ltd. (hereinafter referred to as "LIVINGPHOENIX"), situated at No. 618 Fenghuang Road, Chengdu Tianfu International Bio-town, one of the "Four Zones" within the "One Core, Four Zones" framework of the Western (Chengdu) Science City, is a pioneering high-tech enterprise that specializes in the innovative R&D and smart manufacturing of core components of the extracellular matrix (ECM), including collagen, elastin, and hyaluronic acid, among other active substances.Under the guidance of Dr. Takafumi TAKEBAYASHI, the Biomimetic Collagen Project Team from Japan's JNC Corporation (established in 2002, recognized as one of the world's pioneering non-animal-derived collagen scientific and technological teams), a Ph.D. team from The University of Tokyo, and leveraging the combined strengths of FUNYOU Supply Chain Technology (Chengdu) Co., Ltd. (founded in 2015) and Biomermax Medical Aesthetics Platform Technology Chengdu Co., Ltd. (founded in 2019), LIVINGPHOENIX has emerged as a formidable force.Boasting a fully paid-in registered capital of RMB 36,261,900 among its affiliated enterprises (parent and subsidiary companies) under common control, LIVINGPHOENIX has been identified as a key enterprise for cultivation by the Chengdu Hi-Tech Industrial Development Zone in 2024. The company has also signed a "One Company, One Policy" agreement with the Chengdu Tianfu International Bio-Town Administrative Committee, marking its commitment to becoming a global leader in collagen biomaterials.

The key core technology platform of LIVINGPHOENIX, "POGMENT" , represents the world's first breakthrough in addressing the "thermal stability" issue with its superhelical biomimetic collagen. Its advanced structure has been verified by research teams from the Institute of Process Engineering, Chinese Academy of Sciences, and Shanghai Applied Protein Technology, while its effectiveness has been validated by the Plastic Surgery Department of Peking University Third Hospital and a large-scale beauty and skincare technology company listed on the STAR Market. Furthermore, POGMENT innovatively resolves the viral risks, immunogenicity concerns associated with traditional animal-derived collagen, and the challenge of achieving a stable triple-helical structure in recombinant collagen.

The POGMENT superhelical biomimetic collagen technology originated from Japan's JNC Corporation in 2002 (also a global pioneer in the fermentation-based production of hyaluronic acid). In 2023, it was introduced to Chengdu Tianfu International Bio-Town for large-scale industrialization. Through the research and innovation efforts of Dr. Takafumi TAKEBAYASHI and a full-time Ph.D. team from The University of Tokyo, among others, POGMENT has achieved "independent intellectual property rights," "low-cost supply," and "large-scale production." It is also actively pursuing the filing of invention patents with full independent intellectual property rights (currently under examination by the National Intellectual Property Administration of China) and PCT international patents, with some of these intellectual properties already applied for in China, the United States, the European Union, the United Kingdom, Japan, South Korea, and other jurisdictions.

The product pipeline encompasses the development and production of Class III medical device fillers and implants, Class II medical device dressings, functional skincare products, as well as raw materials for collagen and elastin. Leveraging POGMENT's "versatility in processing shapes" and "technological applicability," the range of application methods and scenarios can be infinitely expanded. Business operations span from bioactive material raw materials to medical and consumer end-products. The market strategy adopts a dual-engine approach focused on China and Japan, while simultaneously pursuing a global layout for collagen products.

The mission of LIVINGPHOENIX is to pursue the dual happiness of material and spiritual well-being for all partners, provide rejuvenating regenerative medicine solutions for humanity, and foster a symbiotic relationship between biotechnology and a better life. Its vision is to establish a century-old enterprise that offers rejuvenating regenerative medicine solutions and promotes happiness.

LIVINGPHOENIX, has forged an innovative R&D ecosystem for biomimetic materials by collaborating with a myriad of esteemed institutions and enterprises, including Intercos, a global beauty manufacturer; Tigermed, a leading medical device CRO enterprise; the Zhejiang Zhongmao company, a global service provider for cosmetics product compliance and quality management; Shanghai OE Biotech, a pioneer in spatial multi-omics technology services; Acer Biosciences, a top preclinical pharmacodynamics evaluation enterprise; WestChina-Frontier Pharma Tech, the National Chengdu Center for New Drug Safety Evaluation; Waters, a leading analytical instrument manufacturer; and Kyushu Institute of Technology in Japan, among others.

This strategic alliance has led to LIVINGPHOENIX's successful recognition in various prestigious forums and initiatives. It has been selected as a recipient of the 2023 EDGE AWARDS Annual Medical & Healthcare Consumer Enterprise by Peimedia Group. Additionally, LIVINGPHOENIX is a participant in the "National Precision Medicine Research and Industrial Development" project for 2024-2025, led by Professor Li Qingfeng, Director of the Plastic and Reconstructive Surgery Department at Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, under the guidance of Professor Rao Keqin from Tsinghua University's Hospital Management Institute and Professor Toshiki MIYAZAKI from Kyushu Institute of Technology.Furthermore, LIVINGPHOENIX has been included in the 2024 graduation project of the Beauty CTO Program at the Shanghai International CTO Academy, East China Normal University, with the founder appointed as an industrial mentor for the period 2024-2028. It is also a member of the China Beautiful and Healthy Industry Forum's Committee of Thirty, chaired by Academician Liao Wangqing of the Chinese Academy of Engineering. LIVINGPHOENIX serves as an initiator of the Anti-Aging Medicine Branch (in preparation) of the China Food and Drug Enterprises Quality and Safety Promotion Association, and holds the position of President in the High-tech and Supply Chain Branch (formerly Procurement and Supply Branch) of the China Cosmetic Surgery Association.

The collaborative R&D product pipeline of LIVINGPHOENIX, and Jland Biotech encompasses "Onlyfun+" (nationally exclusive high-concentration) recombinant human-like collagen of Type III (Class II medical device). Furthermore, the Class III medical device, "Onlyfun+ Recombinant Collagen Freeze-Dried Fiber," has commenced clinical trials at Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital and entered the follow-up phase, with an anticipated market launch in 2025. Meanwhile, the launched product Onlyfun+ has initiated post-market scientific research at Peking University Third Hospital and Beijing Anjia Medical Beauty Clinic.Onlyfun+'s service network spans nearly 500 institutions across 21 cities nationwide, concurrently establishing service networks with leading groups such as Lancy, Huahan, Mylike, Evercare, Aster, and Yestar. It has also developed the country's first autonomous intellectual property-based metaverse anti-aging avatar, "PENNY."

The founding team of LIVINGPHOENIX actively promotes high-quality industrial development by initiating and establishing the China Cosmetic and Plastic Surgery Association's Procurement and Supply Branch (tentatively renamed as the High-tech and Supply Chain Branch) in collaboration with renowned domestic and international enterprises like Bloomage Biotech, Haohai Biological, Alma Lasers, and Shaphar. As a renowned and globally leading initiator and promoter of the "Medical Beauty Capital" endeavor, they have significantly contributed to or led the compilation and review of the "Chengdu Medical Beauty Industry Development Plan (2018-2030)" and the "Chengdu's Policies to Accelerate the Development of the Medical Beauty Industry." They also organized the inaugural China International Medical Beauty Industry Conference and Medical Beauty Capital Summit in 2018 and participated in editing books such as the "Chengdu Medical Beauty Industry Development Report (2019)" and the "Chengdu Medical Beauty Industry Blue Paper (2020)." As CPPCC members and members of the Party for Public Interest, their numerous proposals and suggestions have garnered affirmative instructions from government leaders.

Solidly promoting common prosperity is also a crucial aspect of LIVINGPHOENIX's founding team's commitment to fulfilling social responsibilities, relentless pursuit of renewal and rejuvenation. In response to the pandemic aftermath in 2019, the team organized relevant units under the Procurement and Supply Branch of the China Cosmetic and Plastic Surgery Association to deliver COVID-19-related supplies to 58 grassroots hospitals in Hubei Province, totaling 3.1663 million yuan. In 2020, as the chief organizer, they collaborated with the Sichuan Provincial Youth Federation's medical, educational, and legal sectors to implement targeted poverty alleviation measures in Zhaojue and Ayilumu Township's Asuoluozu Village in Liangshan, donating love supplies and scholarships equivalent to nearly 335,000 yuan (while also arranging teaching ward rounds by medical professionals from Sichuan University's West China Hospital). In 2021, through the Erqi District Charity Federation in Zhengzhou and the Inner Mongolia Autonomous Region Charity Federation, they donated over 600,000 yuan worth of epidemic prevention materials to Zhengzhou and Manzhouli, Inner Mongolia. These efforts have garnered recognitions such as the "Advanced Individual in Poverty Alleviation" award from the Sichuan Provincial Committee of the Revolutionary Committee of the Kuomintang (PRC).

The phoenix, with a history spanning 4,000 years (stemming from ancient Chinese legends of the phoenix and the Egyptian phoenix, evolving alongside Western phoenix myths, and with the Byodo-in Temple's Phoenix Hall in Kyoto recognized as a Japanese national treasure), embodies humanity's aspirations for continuous innovation, rebirth, and eternal youth. Collagen, the most abundant protein in mammals, serves as the "life scaffold" of all animals, featuring a triple-helix structure evolved over millions of years, with origins tracing back to ancient Egypt 6,000 years ago (circa 4000 BCE). Merging the 4,000-year-old "phoenix" regeneration culture, the 6,000-year technological innovation of "collagen," and the 2,500-year-old scientific and aesthetic golden rule of the "Golden Ratio" (0.618), the "LIVINGPHOENIX Superhelix Biomimetic Collagen" mega-science project, located at No. 618 Fenghuang Road, Chengdu Tianfu International Biocity, is poised to make its mark globally.

Guided by the scientific and philosophical value proposition of "Fun Living Phoenix," the LIVINGPHOENIX innovation team focuses on addressing bottlenecks in skin, ligament, tendon, blood vessel wall, cornea, cartilage, and bone regeneration through the development of biomimetic collagen technology. Aiming for the pinnacle of biomimetic technology and industrial development, they uphold the brands "LIVINGPHOENIX," "POGMENT," "SMARTENDER," and "Onlyfun+" in their relentless pursuit of transforming "China Smart Manufacturing" into "World-Class Brands," forging LIVINGPHOENIX into a century-old enterprise offering youthful regenerative medical solutions.

LIVINGPHOENIX warmly invites ambitious and visionary individuals to join us in transforming the world with "Pogment Biomimetic Collagen," embracing the spirit of the phoenix, and Fun Living Phoenix.